GenTraceDx™
Living Cancer Diagnostics

A National Precision Oncology Initiative

This is a Canadian national initiative advancing precision oncology through clinical genomics and real-world implementation.

What is GenTraceDx?

GenTraceDx is a precision oncology platform designed to provide continuously updating clinical intelligence. It integrates:

- Comprehensive genomic and transcriptomic analysis
- Ongoing interpretation of clinical relevance
- Continuous updates as new evidence emerges

Unlike conventional testing, GenTraceDx functions as a **continuously updating clinical intelligence system**, rather than a one-time report.

A CANADIAN COLLABORATION IN CLINICAL GENOMICS

GenTraceDx is being developed through a national collaboration between:

- **Genetrack Biolabs**: a Canadian leader in regulated diagnostics with over 26 years of experience in clinical genomics
- **Canada's Michael Smith Genome Sciences Centre (GSC)**: a world-renowned institution in cancer genomics and clinical sequencing

NATIONAL FUNDING SUPPORT

This initiative is supported through the Genomics Applications Partnership Program (GAPP), funded by:

- **Genome Canada**
- **Genome British Columbia**

These organizations support large-scale, high-impact genomics initiatives aimed at improving healthcare outcomes across Canada.

ABOUT THE GENOME SCIENCES CENTRE (GSC)

The Michael Smith Genome Sciences Centre is one of the world's leading cancer genomics institutions and has played a central role in advancing precision oncology in Canada.

GSC is:

- a key contributor to national cancer genomics programs
- a leader in clinical sequencing and translational genomics
- internationally recognized for its work in cancer research and precision medicine Partnership Program (GAPP).

Clinical Workflow

HOW IT WORKS

1. Patient enrolled through participating clinician
2. Tumour–normal sequencing and RNA analysis performed
3. Initial report delivered
4. Continuous updates as new clinical evidence emerges

Why This Matters

CLINICAL CONTEXT

Current genomic testing approaches are often limited by:

- Fixed gene panels
- Static reporting
- Lack of integration with evolving clinical evidence

GENTRACEDX APPROACH

GenTraceDx enables:

- Matched tumour–normal whole exome sequencing
- Whole-transcriptome RNA analysis
- Identification of therapeutic opportunities (on-label, off-label, and Special Access Program [SAP])
- Continuous reanalysis as new therapies and data become available

GenTraceDx National Pilot (Canada)

GenTraceDx will be evaluated through a 500-patient national pilot across Canada.

OBJECTIVES

- Evaluate clinical utility in real-world oncology settings
- Integrate multiomic analysis into standard workflows
- Expand access to advanced genomic interpretation

TIMELINE

Pilot expected to begin: Fall 2026
Clinician pre-enrollment is now open.

PARTICIPATING SITES

The pilot is open to:

- Oncology centres
- Hospitals
- Academic institutions
- Licensed oncology specialists

To Enroll in the Pilot

The GenTraceDx National Clinical Pilot is expected to begin in Fall 2026. Pre-enrollment is open to physicians and institutions.

Register at:
www.gentrace.com/physician

Enrolled participants will receive onboarding and portal access in advance of the pilot launch and prior to initiating patient referrals.

CLINICAL USE

GenTraceDx is a clinical decision-support platform.

It does not replace physician judgment or institutional protocols. All treatment decisions remain the responsibility of the treating clinician.